ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations

Effects of estrogen receptorβ (ERβ) localization on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer (NSCLC) are unknown. First, we analyzed the relationship between ERβ localization determined by immunohistochemistry and EGFR-TKI outcome...

Full description

Bibliographic Details
Main Authors:	Wang, Zhijie, Li, Zhenxiang, Ding, Xiaosheng, Shen, Zhirong, Liu, Zhentao, An, Tongtong, Duan, Jianchun, Zhong, Jia, Wu, Meina, Zhao, Jun, Zhuo, Minglei, Wang, Yuyan, Wang, Shuhang, Sun, Yu, Bai, Hua, Wang, Jie
Format:	Online
Language:	English
Published:	Nature Publishing Group 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476037/

Similar Items

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
by: Wang, Zhijie, et al.
Published: (2014)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
by: Wang, Shuhang, et al.
Published: (2015)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang, Fen, et al.
Published: (2012)

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
by: Zhu, Jian, et al.
Published: (2012)

Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer
by: Wang, Shuhang, et al.
Published: (2013)

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
by: Bai, Hua, et al.
Published: (2013)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
by: Kuiper, J L, et al.
Published: (2016)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
by: Rajeswara Rao Arasada, et al.
Published: (2018-08-01)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
by: Paz-Ares, Luis, et al.
Published: (2014)

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
by: Duan, Jianchun, et al.
Published: (2015)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
by: Yu, Jiang-Yong, et al.
Published: (2016)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
by: LI, JING, et al.
Published: (2013)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
by: Zheng, D., et al.
Published: (2016)

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
by: Chen, M-C, et al.
Published: (2013)

Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
by: WANG, CHENGDE, et al.
Published: (2015)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
by: Xia, Guo-Hao, et al.
Published: (2014)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
by: Krawczyk, Paweł, et al.
Published: (2015)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
by: Presutti, Dario, et al.
Published: (2015)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
by: Chung, Fu-Tsai, et al.
Published: (2015)

Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
by: Lv, Yang, et al.
Published: (2016)

Unexpected responses to EGFR inhibition in NSCLC
by: Stella, Giulia M., et al.
Published: (2015)

Sulforaphane attenuates EGFR signaling in NSCLC cells
by: Chen, Chi-Yuan, et al.
Published: (2015)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
by: Jung, Minkyu, et al.
Published: (2012)

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
by: Kogure, Yoshihito, et al.
Published: (2015)

Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
by: ZHOU, BO, et al.
Published: (2016)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
by: Zhang, Ruiguang, et al.
Published: (2016)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
by: Matsuo, Norikazu, et al.
Published: (2016)

Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis
by: Zhang, Xinji, et al.
Published: (2012)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
by: Yan, Han, et al.
Published: (2015)

Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance
by: Zhentao Liu, et al.
Published: (2018-08-01)

COMPARISON OF CHEMOTHERAPY RESPONSE AND ADVERSE EFFECTS OF DOUBLE-PLATINUM PLUS EGFR-TKI VERSUS DOUBLE-PLATINUM ALONE ON NSLCLC PATIENTS WITH DISEASE PROGRESSION AND EGFR-TKI TREATMENT
by: Laksmi Wulandari, et al.
Published: (2017-12-01)

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer
by: Yang, Xue, et al.
Published: (2016)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
by: Wu, Hong, et al.
Published: (2015)

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
by: Sasada, Tetsuro, et al.
Published: (2013)

DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations
by: Nozaki, Koichiro, et al.
Published: (2014)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
by: Wu, Xuan, et al.
Published: (2013)

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
by: Dufort, Sandrine, et al.
Published: (2011)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
by: Russo, Alessandro, et al.
Published: (2015)

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
by: Douillard, Jean-Yves, et al.
Published: (2014)

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
by: So, Kwang Sup, et al.
Published: (2014)